ARS Pharmaceuticals, Inc. Amortization of Debt Issuance Costs
ARS Pharmaceuticals, Inc. (SPRY) reported Amortization of Debt Issuance Costs of $0 for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-11-02.
Discontinued › Operating Expenses
us-gaap:AmortizationOfFinancingCosts · last filed 2022-11-02
- ARS Pharmaceuticals, Inc. amortization of debt issuance costs for the quarter ending 2021-12-31 was $0.00, a 100.00% decline year-over-year.
- ARS Pharmaceuticals, Inc. amortization of debt issuance costs for the quarter ending 2021-09-30 was $0.00, a 100.00% decline year-over-year.
- ARS Pharmaceuticals, Inc. amortization of debt issuance costs for the quarter ending 2021-06-30 was $1.00K, a 80.00% decline year-over-year.
- ARS Pharmaceuticals, Inc. amortization of debt issuance costs for the quarter ending 2021-03-31 was $1.00K, a 95.00% decline year-over-year.
- ARS Pharmaceuticals, Inc. amortization of debt issuance costs for fiscal 2021 was $2.00K, a 93.55% decline from fiscal 2020.
- ARS Pharmaceuticals, Inc. amortization of debt issuance costs for fiscal 2020 was $31.00K.
| Period end | Amortization of Debt Issuance Costs 3 month | Amortization of Debt Issuance Costs 6 month | Amortization of Debt Issuance Costs 9 month | Amortization of Debt Issuance Costs 12 month |
|---|---|---|---|---|
| 2022-09-30 | $0.00 10-Q · filed 2022-11-02 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $0.00 derived: sum of 2 quarters · filed 2022-11-02 | $1.00K derived: sum of 3 quarters · filed 2022-11-02 | $2.00K 10-K · filed 2022-03-31 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $1.00K derived: sum of 2 quarters · filed 2022-11-02 | $2.00K 10-Q · filed 2022-11-02 | $5.00K derived: sum of 4 quarters · filed 2022-11-02 |
| 2021-06-30 | $1.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $2.00K 10-Q · filed 2021-08-12 | $5.00K derived: sum of 3 quarters · filed 2022-03-31 | $8.00K derived: sum of 4 quarters · filed 2022-03-31 |
| 2021-03-31 | $1.00K 10-Q · filed 2021-05-13 | $4.00K derived: sum of 2 quarters · filed 2022-03-31 | $7.00K derived: sum of 3 quarters · filed 2022-03-31 | $12.00K derived: sum of 4 quarters · filed 2022-03-31 |
| 2020-12-31 | $3.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $6.00K derived: sum of 2 quarters · filed 2022-03-31 | $11.00K derived: sum of 3 quarters · filed 2022-03-31 | $31.00K 10-K · filed 2022-03-31 |
| 2020-09-30 | $3.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $8.00K derived: sum of 2 quarters · filed 2021-11-10 | $28.00K 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $5.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $25.00K 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | $20.00K 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |